Roche
NICE approves Roche’s Perjeta for breast cancer
November 16, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Perjeta, Roche, breast cancer
NICE has announced its approval of Roche’s Perjeta (pertuzumab) as a neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or early-stage …
Roche, Bayer and more speak out against German pricing cap plans
November 14, 2016Sales and Marketing Bayer, Germany, Roche
A number of major drug manufacturers have spoken out against German government plans to cap prescription drug pricing in the …
MSD’s Keytruda early success ends trial early
October 24, 2016Sales and Marketing MSD, Merck, Roche, keytruda, opdivo, tecentriq
MSD, known as Merck in the US, ended their Phase III trial of Keytruda for treatment of advanced urothelial cancer …
Roche’s immunotherapy cancer drug given FDA approval
October 19, 2016Research and Development Cancer, FDA, Genentech, Roche, immunotherapy, lung cancer
Coming off the back of earlier positive news this month, Roche has revealed that their drug, Tecentriq, has been given …
Novartis’ Zykadia more effective than chemo, new study shows
October 13, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia
Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
Tesaro’s ovarian cancer drug success threatens market rivals
October 12, 2016Research and Development AbbVie, AstraZeneca, Pfizer, Roche, Tesaro, avastin, lynparza, niraparib, talazoparib, veliparib
Phase III results from Tesaro’s niraparib PARP inhibitor could spell trouble for rivals Roche and AstraZeneca as its showed sizeable …
Roche granted further good news by FDA
October 11, 2016Manufacturing and Production Actembra, Alecensa, FDA, Lucentis, Roche, United States, america
Roche was given further good news by FDA after receiving a Priority Review for its Lucentis drug – this news …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
Roche granted breakthrough therapy designation by FDA
October 5, 2016Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy
Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …
Roche’s Alecensa receives second FDA Breakthrough Therapy Designation
October 4, 2016Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib
Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
NICE rejects expanded treatment indication for Roche’s Esbriet
September 19, 2016Sales and Marketing Esbriet, NICE, Roche, rejection
NICE has published a final appraisal rejecting the expanded use of Roche’s Esbriet (pirfenidone) for the treatment of early idiopathic …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
Roche’s Ocrevus more effective than Merck’s Rebif, company claims
September 14, 2016Research and Development Merck, Ocrevus, Rebif, Roche, multiple sclerosis
Roche has announced new results from the Phase III studies of investigational medicine Ocrevus (ocrelizumab) studying relapsing multiple sclerosis (RMS) …
Gilead appoints former Roche executive
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, Roche, appointment
Gilead Sciences has hired Rogers Luo as vice president and general manager of commercial operations in China. Luo formerly served …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
